257 related articles for article (PubMed ID: 11855881)
1. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
[TBL] [Abstract][Full Text] [Related]
2. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
3. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
[TBL] [Abstract][Full Text] [Related]
4. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
5. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
6. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
[TBL] [Abstract][Full Text] [Related]
7. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
8. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Slichenmyer WJ; Donehower RC; Chen TL; Bowling MK; McGuire WP; Rowinsky EK
Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions.
Del Priore G; Smith P; Warshal DP; Dubeshter B; Angel C
Gynecol Oncol; 1995 Feb; 56(2):316-8. PubMed ID: 7896206
[TBL] [Abstract][Full Text] [Related]
11. Taxol hypersensitivity: rapid retreatment is safe and cost effective.
Olson JK; Sood AK; Sorosky JI; Anderson B; Buller RE
Gynecol Oncol; 1998 Jan; 68(1):25-8. PubMed ID: 9454655
[TBL] [Abstract][Full Text] [Related]
12. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
13. Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
Yanaranop M; Chaithongwongwatthana S
Asia Pac J Clin Oncol; 2016 Sep; 12(3):289-99. PubMed ID: 27098551
[TBL] [Abstract][Full Text] [Related]
14. [Weekly administration of low-dose paclitaxel for advanced or metastatic breast cancer].
Uno Y; Hirano M; Murakami N; Kikuchi T; Nozawa H; Okuda T; Oya J; Kikkawa H
Gan To Kagaku Ryoho; 2002 Feb; 29(2):227-32. PubMed ID: 11865628
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel premedication regimens.
Boehm DK; Maksymiuk AW
J Natl Cancer Inst; 1996 Apr; 88(7):463-5. PubMed ID: 8618242
[No Abstract] [Full Text] [Related]
16. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Köppler H; Heymanns J; Weide R
Onkologie; 2001 Jun; 24(3):283-5. PubMed ID: 11455223
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis for paclitaxel hypersensitivity reactions.
Kintzel PE
Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
[TBL] [Abstract][Full Text] [Related]
18. [Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
Kumagai M; Fujii T; Komatsu M; Kusuda T; Takehara K; Shinkou S; Naitou H
Gan To Kagaku Ryoho; 2004 Apr; 31(4):555-9. PubMed ID: 15114699
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
[TBL] [Abstract][Full Text] [Related]
20. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]